Anti-MRSA agents: under investigation, in the exploratory phase and clinically available

Abstract

Staphylococcal infections are difficult to treat due to the rapid emergence of methicillin-resistant staphylococci and, unfortunately, vancomycin-intermediate or -resistant staphylococci. Numerous alternative treatments are urgently required. In this special report, intensive research of new molecules is highlighted – in known antibacterial families and new medicinal chemical entities.

Keywords::

• anti-MRSA
• cephems
• glycopeptides
• MRSA